Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage III Renal Cell Cancer: early-phase trial registry
2 of 5 indexed Stage III Renal Cell Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Stage III Renal Cell Cancer: 5 US clinical trials tracked, 2 recruiting.
Stage III Renal Cell Cancer is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Andrei Iagaru, running 1 of these trials.
Enrollment posture brief
Registry condition stage-iii-renal-cell-cancer
OPEN 2 | RECR 40% | LATE 0 | EARLY 4 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)
Stage III Renal Cell Cancer lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage III Renal Cell Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage III Renal Cell Cancer is recruiting below its size-band peers.
2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage III Renal Cell Cancer research.
Andrei Iagaru accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Stage III Renal Cell Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 89 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.
-
Stage III Renal Cell Cancer research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
Jonsson Comprehensive Cancer Center
NCT06447103
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
Rahul Aggarwal
NCT03682289
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
University of Southern California
NCT02664883
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Children's Oncology Group
NCT00335556
18F-FSPG PET/CT for Cancer Patients on Therapy
Andrei Iagaru
NCT02599194
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage III Renal Cell Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage III Renal Cell Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage III Renal Cell Cancer page
5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Stage III Renal Cell Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Andrei Iagaru sponsors the most Stage III Renal Cell Cancer trials on record, review their full trial history before evaluating a specific study. See Andrei Iagaru's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage III Renal Cell Cancer condition card totals 5 registered trials; most-linked intervention Magnetic Resonance Imaging; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.